Niagen Bioscience (NAGE) Income from Continuing Operations (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly Income from Continuing Operations of 6318000.0 for Q1 2026, up 24.79% year-over-year from 5063000.0 in Q1 2025, and up 52.9% quarter-over-quarter from 4132000.0 in Q4 2025.
Niagen Bioscience (NAGE) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Income from Continuing Operations for 17 consecutive years, with 6318000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 24.79% year-over-year to 6318000.0; the TTM figure through Mar 2026 stood at 18637000.0 (up 32.13% YoY), while the FY2025 annual figure was 17382000.0, up 103.3% from the prior year.
- Income from Continuing Operations rose to 6318000.0 in Q1 2026 per NAGE's latest filing, from 4132000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 7179000.0 in Q4 2024 and bottomed at 11657000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 968352.94 across 5 years, with a median of 270000.0 in 2023.
- On a YoY basis, Income from Continuing Operations climbed as much as 24160.0% in 2025 and fell as far as 42.44% in 2025.
- Niagen Bioscience's Income from Continuing Operations stood at 1579000.0 in 2022, then surged by 82.9% to 270000.0 in 2023, then jumped by 2758.89% to 7179000.0 in 2024, then sank by 42.44% to 4132000.0 in 2025, then jumped by 52.9% to 6318000.0 in 2026.
- Business Quant data shows NAGE's Income from Continuing Operations at 6318000.0 in Q1 2026, 4132000.0 in Q4 2025, and 4578000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 963,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 963,000.00 |
| Mar 31, 2026 | 6.32 Mn |
| Dec 31, 2025 | 4.13 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 3.61 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 7.18 Mn |
| Sep 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | -492,000.00 |
| Dec 31, 2023 | -270,000.00 |
| Sep 30, 2023 | -5.39 Mn |
| Jun 30, 2023 | -6.79 Mn |
| Mar 31, 2023 | -6.68 Mn |
| Dec 31, 2022 | -1.58 Mn |
| Sep 30, 2022 | -8.11 Mn |
| Jun 30, 2022 | -11.66 Mn |
| Mar 31, 2022 | -8.23 Mn |
| Dec 31, 2021 | -4.85 Mn |
| Sep 30, 2021 | -9.68 Mn |